VIVID Pill Counter Business Growth
VIVID sales in the third quarter were up 50% compared to the second quarter of this year and 12% compared to the same quarter last year. The development of a new VIVID workstation is expected to be a game-changer in the market.
Cost-Cutting Initiatives
The company successfully reduced operating expenses by over $1 million, or roughly 22%, compared to the same time frame last year, and improved cash burn rate without affecting the top line.
Bioprocessing Segment Performance
Sales compared to last year were up 12%, with improved gross margins and lower expenditures, resulting in a 27% improvement in EBITDA. The U.S. team reported a breakeven result with a positive EBITDA margin of 14%.
Strong Pipeline and New Product Development
A 90% increase in the commercial pipeline value was reported, alongside significant advancements in key projects such as the development of PAH technology and the new generation of the liquid injection system.
Strategic Partnerships
Secured partnerships and endorsements from major industry players like Merck, which are expected to positively influence the company's commercial track.